Researchers performed an analysis to determine whether recombinant VWF given with surgery would be safe and effective in preventing bleeding in patients with VWD.
Does the von Willebrand factor antigen/ADAMTS13 ratio contribute to immunothrombosis and predict mortality in patients with COVID-19?
Whether inherited or acquired, bleeding disorders can cause significant pain, inconvenience, and stress in a person’s life. When patients think they or a loved one may have a bleeding disorder, what should they know?
These guidelines from ASH, ISTH, NHF, and WFH are intended to support patients, clinicians, and healthcare professionals in their decisions affecting the management of VWD.
A population-based analysis suggested that plasma levels of von Willebrand factor may be a potential biomarker for the future risk of incident venous thromboembolism.
Predicting bleeding during cardiopulmonary bypass is complex and not captured by tests, including measuring von Willebrand factor interaction.
Research presented at the 2020 annual meeting of the American Society of Hematology reveals semiautomatic densitometric analysis of von Willebrand factor multimers to have excellent accuracy in clinical practice.
Epidural analgesia in pregnant women with VWD type 1 appears to be safe with VWF and factor VIII levels of 80% or more in the third trimester.
ABO blood group has been associated with cardiovascular disease and thrombotic risk; however, influences on hemostasis are still not well understood.
Researchers studied the effect of certain biomarkers on long-term adverse cardiovascular outcomes in patients with coronary morbidities undergoing PCI.
